Proteomics in Alzheimer's disease focuses on identifying and analyzing the complex network of proteins involved in its pathogenesis. This approach aims to uncover biomarkers for early diagnosis, track disease progression, and identify therapeutic targets. By analyzing protein profiles in brain tissues, cerebrospinal fluid, or blood samples, proteomics enables researchers to understand the molecular mechanisms underlying Alzheimer's disease and dementia.
Recent advancements in proteomic technologies such as mass spectrometry and protein microarrays have allowed for the discovery of novel protein biomarkers that reflect pathological changes in the brain, offering potential insights into disease mechanisms and personalized treatment strategies. Ultimately, proteomics holds promise in revolutionizing our understanding and management of Alzheimer's disease by providing valuable tools for early detection and targeted intervention.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States